# Sermorelin

Sermorelin has 34 registered human trials. It is marketed for 4 different uses.

**In short**

- 34 registered human trials exist for Sermorelin.
- Sermorelin is not FDA-approved for any use.
- What has actually been studied: growth hormone deficiency, lipodystrophy, hiv infections.
- Last checked against ClinicalTrials.gov on 2026-07-27.

## What it is sold for

- Anti-aging
- Muscle & body composition
- Sleep
- Energy

## What has actually been tested

- Growth Hormone Deficiency
- Lipodystrophy
- HIV Infections
- Metabolic Associated Steatotic Liver Disease
- Nonalcoholic Steatohepatitis
- Hepatic Steatosis
- Infertility, Female
- Mild Cognitive Impairment
- Abdominal Obesity
- Type 2 Diabetes
- HIV Lipodystrophy Syndrome
- Body Composition
- Healthy Volunteers
- Sleep Disorders
- Aging
- HIV
- Non-Alcoholic Fatty Liver Disease
- Obesity
- Obesity, Abdominal
- Liver Fat
- Fatty Liver
- Congestive Heart Failure
- Short Stature
- Subfertility
- HIV Lipodystrophy
- Normal Healthy Volunteers
- Human Immunodeficiency Virus (HIV)
- Nonalcoholic Fatty Liver Disease (NAFLD)
- Nonalcoholic Steatohepatitis (NASH)
- Elderly
- Healthy Volunteer Study
- Healthy
- HIV-1-infection
- Frailty
- Impaired Physical Function
- Diagnosis of Adult Growth Hormone Deficiency (AGDH)
- Hormone Deficiency
- Sleep Disorder
- Traumatic Brain Injury

## Every trial on record

| Trial ID | Title | Condition | Phase | Status | Enrolled |
|---|---|---|---|---|---|
| [NCT01359488](https://clinicaltrials.gov/study/NCT01359488) | VRS-317 in Adult Subjects With Growth Hormone Deficiency | Growth Hormone Deficiency | Phase 1 | COMPLETED | 50 |
| [NCT00608023](https://clinicaltrials.gov/study/NCT00608023) | TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy | Lipodystrophy, HIV Infections | Phase 3 | COMPLETED | 263 |
| [NCT07481734](https://clinicaltrials.gov/study/NCT07481734) | Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) | Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | RECRUITING | 120 |
| [NCT06701071](https://clinicaltrials.gov/study/NCT06701071) | Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation | Infertility, Female | Phase 4 | RECRUITING | 120 |
| [NCT02553603](https://clinicaltrials.gov/study/NCT02553603) | The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment | Mild Cognitive Impairment | Phase 1 | COMPLETED | 22 |
| [NCT00675506](https://clinicaltrials.gov/study/NCT00675506) | Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese | Abdominal Obesity, Growth Hormone Deficiency | Phase 2 | COMPLETED | 60 |
| [NCT01264497](https://clinicaltrials.gov/study/NCT01264497) | Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes | Type 2 Diabetes | Phase 2 | COMPLETED | 55 |
| [NCT03226821](https://clinicaltrials.gov/study/NCT03226821) | Body Composition and Adipose Tissue in HIV | HIV Lipodystrophy Syndrome, Growth Hormone Deficiency | Phase 4 | TERMINATED | 6 |
| [NCT00850564](https://clinicaltrials.gov/study/NCT00850564) | Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men | Healthy Volunteers | Not phased | COMPLETED | 15 |
| [NCT03018886](https://clinicaltrials.gov/study/NCT03018886) | Diagnosing Adult Growth Hormone Deficiency | Growth Hormone Deficiency | Not phased | COMPLETED | 160 |
| [NCT01060488](https://clinicaltrials.gov/study/NCT01060488) | Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency | Growth Hormone Deficiency | Phase 3 | COMPLETED | 69 |
| [NCT00000380](https://clinicaltrials.gov/study/NCT00000380) | Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances | Sleep Disorders | Not phased | COMPLETED | — |
| [NCT00257712](https://clinicaltrials.gov/study/NCT00257712) | SMART: Somatotrophics, Memory, and Aging Research Trial | Aging, Mild Cognitive Impairment | Phase 2 | COMPLETED | 151 |
| [NCT00720902](https://clinicaltrials.gov/study/NCT00720902) | Adult Growth Hormone Deficiency and Cardiovascular Risk | Growth Hormone Deficiency | Phase 4 | TERMINATED | 7 |
| [NCT02012556](https://clinicaltrials.gov/study/NCT02012556) | Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients | HIV | Phase 1 | COMPLETED | 18 |
| [NCT03375788](https://clinicaltrials.gov/study/NCT03375788) | Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk | Non-Alcoholic Fatty Liver Disease, Obesity | Phase 2 | COMPLETED | 51 |
| [NCT00791843](https://clinicaltrials.gov/study/NCT00791843) | The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure | Congestive Heart Failure | Phase 2 | COMPLETED | 3 |
| [NCT01237041](https://clinicaltrials.gov/study/NCT01237041) | Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children | Obesity, Short Stature | Phase 2 | TERMINATED | 37 |
| [NCT00123253](https://clinicaltrials.gov/study/NCT00123253) | TH9507 in Patients With HIV-Associated Lipodystrophy | HIV Infections, Lipodystrophy | Phase 3 | COMPLETED | 412 |
| [NCT02736591](https://clinicaltrials.gov/study/NCT02736591) | Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian Response | Subfertility | Phase 3 | UNKNOWN | 210 |
| [NCT01263717](https://clinicaltrials.gov/study/NCT01263717) | Effects of Growth Hormone Releasing Hormone in HIV | HIV, HIV Lipodystrophy | Not phased | COMPLETED | 54 |
| [NCT01701973](https://clinicaltrials.gov/study/NCT01701973) | Effect of DPP4 Inhibition on Growth Hormone Secretion | Obesity | Phase 4 | COMPLETED | 44 |
| [NCT01632592](https://clinicaltrials.gov/study/NCT01632592) | Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue | Abdominal Obesity | Not phased | WITHDRAWN | 0 |
| [NCT02271282](https://clinicaltrials.gov/study/NCT02271282) | Estradiol-Receptor Blockade in Older Men and Women | Normal Healthy Volunteers | Phase 1 | COMPLETED | 40 |
| [NCT00795210](https://clinicaltrials.gov/study/NCT00795210) | Effects of Short-term Growth Hormone in HIV-infected Patients | HIV Lipodystrophy | Not phased | COMPLETED | 25 |
| [NCT02196831](https://clinicaltrials.gov/study/NCT02196831) | Tesamorelin Effects on Liver Fat and Histology in HIV | Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD) | Not phased | COMPLETED | 61 |
| [NCT00807365](https://clinicaltrials.gov/study/NCT00807365) | Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly | Elderly | Phase 2 | TERMINATED | 5 |
| [NCT00324064](https://clinicaltrials.gov/study/NCT00324064) | Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing | Growth Hormone Deficiency | Not phased | COMPLETED | 90 |
| [NCT03031535](https://clinicaltrials.gov/study/NCT03031535) | Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers | Healthy Volunteer Study | Phase 1 | COMPLETED | 32 |
| [NCT01897844](https://clinicaltrials.gov/study/NCT01897844) | A Two Part Phase 1, Repeated Doses and Continuous Infusion Study With ITF2984 in Healthy Volunteers | Healthy | Phase 1 | COMPLETED | 36 |
| [NCT06554717](https://clinicaltrials.gov/study/NCT06554717) | Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV | HIV-1-infection, Frailty | Phase 2 | RECRUITING | 100 |
| [NCT00448747](https://clinicaltrials.gov/study/NCT00448747) | Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test. | Diagnosis of Adult Growth Hormone Deficiency (AGDH) | Phase 3 | COMPLETED | 101 |
| [NCT01410799](https://clinicaltrials.gov/study/NCT01410799) | Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly | Hormone Deficiency, Aging | Phase 2 | TERMINATED | 13 |
| [NCT02931474](https://clinicaltrials.gov/study/NCT02931474) | Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia | Sleep Disorder, Traumatic Brain Injury | Phase 2 | WITHDRAWN | 0 |

## Common questions

**How many human trials does Sermorelin have?**
34, each listed above with a link to its original record.

**Is Sermorelin FDA approved?**
No. It is not approved by the FDA for any indication.

**Where does this data come from?**
ClinicalTrials.gov. We count interventional human studies only. Every trial
links to its original record.

---

*Automated aggregation from public registries. Not medical advice. No physician
has reviewed this page. Source: https://www.whatsactuallyknown.com/compounds/sermorelin*